Changes continue at E-Systems,the parent of PACS developer Advanced Video Products (AVP). TheDallas-based firm has acquired two archival companies and mergedthem into a new subsidiary, EMASS. The new subsidiary will developproducts that will have
Changes continue at E-Systems,the parent of PACS developer Advanced Video Products (AVP). TheDallas-based firm has acquired two archival companies and mergedthem into a new subsidiary, EMASS. The new subsidiary will developproducts that will have applications in medical imaging, accordingto E-Systems.
The acquired companies are Advanced Archival Products (AAP),a Littleton, CO, developer of storage management software forclient-server environments, and Grau Automation, a manufacturerof automated tape libraries, which is located near Stuttgart,Germany. E-Systems also spun off its mass storage operations intothe new subsidiary. E-Systems executive Mitchell Bohn has beenappointed president and COO of EMASS, to be based in Dallas.
E-Systems has been making moves to reposition itself in themedical market. The company let go 13 employees from AVP lastmonth, but at the same time said it remains committed to medicalimaging (SCAN 9/28/94).
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.